Article
Antiapoptotic mechanism of cannabinoid receptor 2 agonist on cisplatin-induced apoptosis in the HEI-OC1 auditory cell line.
Department of Pharmacology, College of Oriental Medicine, Kyung Hee University, Seoul, Republic of Korea.
Journal of Neuroscience Research (impact factor:
2.74).
04/2007;
85(4):896-905.
DOI:10.1002/jnr.21168
Source: PubMed
-
Citations (0)
- Cited In (1)
-
Article: Cannabinoid receptor agonist protects cultured dopaminergic neurons from the death by the proteasomal dysfunction.
[show abstract] [hide abstract]
ABSTRACT: Cannabinoids have been proposed to possess neuroprotective properties; though their mechanism of action remains contentious, they are posited to prevent neurodegenerative disorders, including Parkinson's disease, the pathogenesis of which has not been established. Recent studies have demonstrated that induction of proteasomal dysfunction in animal models results in a phenotype similar to Parkinson's disease. Here, we investigated the neuroprotective function of a synthetic cannabinoid-receptor agonist (WIN55.212.2) in dopaminergic neuronal death induced by a proteasomal synthase inhibitor (PSI), additionally testing the hypothesis that WIN55.212.2 modulates cytoplasmic accumulation of parkin and α-synuclein, a key feature of proteasomal dysfunction in Parkinson's. WIN55.212.2 protects PC12 cells from PSI-induced cytotoxicity, concomitantly inhibiting PSI-induced polyADP ribose polymerase expression and activation of caspase-3. While PSI induces cytoplasmic accumulation of α-synuclein and parkin, WIN55.212.2 counters these effects. Interestingly, however, while PSI induces the activation and nuclear translocalization of nuclear factor κB, WIN55.212.2 potentiates this effect. These data are suggestive that WIN55.212.2 might confer a neuroprotective benefit in PSI-induced proteasomal dysfunction, and could further protect against neuronal degeneration stemming from cytoplasmic accumulation of α-synuclein and parkin. These results indicate that WIN55.212.2 may be a candidate for treatment of neurodegenerative diseases, including Parkinson's disease.Anatomy & cell biology 06/2011; 44(2):135-42.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
Activation
auditory cell line HEI-OC1
cannabinoid receptor 2
chemotherapy
Cisplatin
cisplatin ototoxicity
cisplatin-induced apoptosis
cisplatin-treated HEI-OC1 cells
cochlear hair cell loss
DNA fragmentation
dose-dependent manner
effective chemotherapeutic agent
extracellular signal-regulated kinase pathway
FACS analysis
harmful side effects
JWH-015 inhibited cisplatin-induced reactive oxygen species
MTT assay
poly-(ADP)-ribose polymerase
significant ototoxic side effects
tumor necrosis factor-alpha production